Digital Voice Biomarkers in Upper Airway Health

Abstract

Digital voice biomarkers are rapidly emerging as a novel, non-invasive approach for assessing upper airway health. By extracting and analyzing specific acoustic features from voice recordings, clinicians can potentially detect airway pathology and monitor disease progression in various conditions such as obstructive sleep apnea, laryngeal disorders, and post-surgical changes. This review synthesizes current evidence on the use of digital voice biomarkers, explores their pathophysiological basis, highlights associated risk factors, outlines clinical features, and discusses diagnostic utility, management implications, and future directions. The integration of digital voice analysis into routine clinical practice holds promise for enhancing diagnostic accuracy, enabling remote monitoring, and personalizing therapies for upper airway disorders.

Introduction

The human voice, a complex product of respiratory, laryngeal, and supraglottic coordination, offers rich physiological data that can reflect the health of the upper airway. Recent advances in digital signal processing and machine learning have enabled the extraction of subtle acoustic patterns termed "digital voice biomarkers" from ordinary speech. These biomarkers are now being explored for their diagnostic and prognostic value in a spectrum of upper airway disorders. Given the constraints of conventional assessment methods, such as the invasiveness of endoscopy or the logistical burden of polysomnography, digital voice biomarkers offer a compelling, patient-friendly alternative for ongoing monitoring and early detection. For healthcare professionals, understanding the science and clinical application of digital voice biomarkers is critical as these tools transition from research to practice.

Epidemiology / Disease Burden

Upper airway disorders, including obstructive sleep apnea (OSA), laryngeal dysfunction, and chronic rhinosinusitis, represent a significant global health burden. OSA alone affects nearly 1 billion adults worldwide, many of whom remain undiagnosed due to resource constraints and limited access to specialized testing. Laryngeal pathologies, including vocal fold paralysis and benign lesions, contribute to dysphonia and impaired quality of life. The chronic nature of these conditions necessitates long-term monitoring, often hindered by patient discomfort and health system inefficiencies. Digital voice biomarkers, enabling remote and scalable assessments, have the potential to transform disease surveillance, particularly in underserved populations and telemedicine settings.

Pathophysiology

Voice production depends on the integrity and coordinated function of upper airway structures, including the vocal folds, supraglottic tract, and respiratory support. Pathological changes such as edema, neuromuscular dysfunction, or airway obstruction alter the vibratory characteristics and resonance properties of the vocal tract. These changes manifest as measurable variations in voice acoustics, including alterations in pitch, jitter, shimmer, harmonics-to-noise ratio, and formant frequencies. Digital signal processing algorithms can quantify these parameters, and machine learning models can identify disease-specific patterns, forming the basis of digital voice biomarker technology.

Risk Factors

Risk factors for upper airway disorders detectable via voice biomarkers include obesity (increasing risk for OSA), smoking (predisposing to laryngeal pathology), aging (leading to sarcopenia and vocal fold atrophy), occupational voice use (e.g., teachers, singers), neurological disease (e.g., Parkinson’s disease), and prior head and neck surgery or irradiation. Environmental exposures, such as allergens and air pollutants, also contribute to chronic inflammation and structural changes affecting voice. Recognizing these risk factors aids in targeted screening and interpretation of voice biomarker data.

Clinical Features

Common clinical manifestations of upper airway compromise include hoarseness, breathiness, stridor, reduced vocal endurance, and sleep-disordered breathing symptoms. Subtle changes may precede overt symptoms, providing a window for early detection. Voice biomarker analysis can detect such changes before they are clinically apparent, enabling preemptive intervention. In OSA, for instance, increased pharyngeal collapsibility alters voice resonance, while in laryngeal pathologies, impaired glottic closure affects jitter and shimmer parameters. These features can be objectively tracked over time using digital tools.

Diagnosis

Traditional diagnosis of upper airway disorders relies on clinical examination, laryngoscopy, polysomnography, or imaging modalities that can be invasive, expensive, or logistically challenging. Digital voice biomarker analysis offers a non-invasive, rapid, and repeatable alternative. Using smartphone or dedicated microphone recordings, signal processing algorithms extract acoustic features for comparison against normative or disease-specific databases. Recent studies have demonstrated the feasibility and accuracy of voice biomarker analysis for screening OSA, predicting surgical outcomes, and distinguishing between benign and malignant laryngeal lesions. Integration with telemedicine platforms further enhances accessibility.

Treatment & Management

Digital voice biomarkers have growing utility in guiding and monitoring treatment. In sleep apnea, they can help track response to continuous positive airway pressure (CPAP) therapy or oral appliances by assessing changes in voice resonance. For laryngeal disorders, voice biomarker trends can reflect therapeutic efficacy whether from speech therapy, pharmacological interventions, or surgery. Regular, remote monitoring encourages patient engagement and allows clinicians to adjust interventions proactively, minimizing complications and optimizing outcomes.

Recent Advances / Emerging Therapies

Recent advances include the development of machine learning models trained on large, annotated voice datasets for high-accuracy disease classification. Deep learning techniques are being used to identify novel, non-obvious biomarkers, potentially improving sensitivity and specificity. Integration with wearable devices and smart assistants enables passive, longitudinal monitoring. Emerging therapies leveraging biofeedback, guided by real-time voice biomarker analysis, may offer new avenues for rehabilitation. Research is ongoing to validate these technologies across diverse populations and languages, ensuring generalizability and equity in clinical application.

Guideline Recommendations

While formal guidelines are still evolving, leading professional bodies acknowledge the promise of digital biomarkers in precision medicine and telehealth. The American Academy of Sleep Medicine and the American Laryngological Association recommend continued research and controlled trials to establish the clinical validity and utility of digital voice biomarkers. Interim guidance encourages the use of voice analysis as a supplementary screening or monitoring tool, particularly in resource-limited or remote settings, with results interpreted in conjunction with standard clinical assessments.

Conclusion

Digital voice biomarkers represent a transformative innovation in the assessment and management of upper airway health. With ongoing advances in signal processing, machine learning, and digital health infrastructure, these tools are poised to augment traditional diagnostic pathways, enable personalized care, and expand access to monitoring for vulnerable populations. Continued research, clinical validation, and interdisciplinary collaboration are essential to realize the full potential of digital voice biomarkers in routine clinical practice.